Literature DB >> 7944938

Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head?

O Ishikawa1, H Ohigashi, S Imaoka, Y Sasaki, T Iwanaga, Y Matayoshi, T Inoue.   

Abstract

OBJECTIVE: To determine whether or not both regional control and long-term survival rate were improved by preoperative irradiation prior to curative pancreatectomy for adenocarcinoma of the pancreatic head.
DESIGN: Retrospective study of recorded medical data from 1985 to 1989.
SETTING: The Center for Adult Diseases, Osaka, one of the major cancer centers in Japan. PATIENTS AND INTERVENTION: Fifty-four consecutive patients in whom pancreatic head cancer had been judged to be resectable by preoperative diagnostic techniques. A total of 50 Gy per 10 MeV of x-ray was irradiated preoperatively to the wide field, including the pancreatic head area, in 23 patients (group A) but not in the 31 remaining patients (group B). The background factors before treatment did not differ between these two groups. OUTCOME MEASURES: Resectability, postoperative survival, and modes of cancer recurrence.
RESULTS: At laparotomy, curative pancreatectomy was possible in 17 patients (74%) in group A and 19 (61%) in group B (not significant). In patients undergoing resection, the 1-year survival rate was 75% in group A and 43% in group B (P < .05). However, 3- and 5-year survival rates were almost the same in both groups (28% vs 32% and 22% vs 26%, respectively). With regard to the cause of death after pancreatectomy, group A had a significantly lower incidence of deaths due to regional recurrence within 1.5 postoperative years compared with group B, whereas deaths due to hepatic metastasis were markedly higher after 1 postoperative year in group A compared with group B.
CONCLUSIONS: Preoperative irradiation prior to pancreatectomy succeeded in reducing the incidence of early deaths due to regional recurrence. However, owing to the next barrier--death due to hepatic metastasis after 1 postoperative year--long-term (3- and 5-year) survival rate was not improved at all.

Entities:  

Mesh:

Year:  1994        PMID: 7944938     DOI: 10.1001/archsurg.1994.01420340089017

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  21 in total

Review 1.  Adjuvant therapy in pancreatic cancer.

Authors:  P Ghaneh; J Slavin; R Sutton; M Hartley; J P Neoptolemos
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).

Authors:  J P Neoptolemos; P Baker; H Beger; K Link; P Pederzoli; C Bassi; C Dervenis; H Friess; M Büchler
Journal:  Int J Pancreatol       Date:  1997-04

3.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Authors:  C J Yeo; R A Abrams; L B Grochow; T A Sohn; S E Ord; R H Hruban; M L Zahurak; W C Dooley; J Coleman; P K Sauter; H A Pitt; K D Lillemoe; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

4.  The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection.

Authors:  H Ozaki; T Hiraoka; R Mizumoto; S Matsuno; Y Matsumoto; T Nakayama; T Tsunoda; T Suzuki; M Monden; Y Saitoh; H Yamauchi; Y Ogata
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

5.  Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.

Authors:  V K Mehta; G Fisher; J A Ford; J C Poen; M A Vierra; H Oberhelman; J Niederhuber; J A Bastidas
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

6.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

Review 7.  A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer.

Authors:  Jerome Martin Laurence; Peter Duy Tran; Kavita Morarji; Guy D Eslick; Vincent Wai To Lam; Charbel Sandroussi
Journal:  J Gastrointest Surg       Date:  2011-09-13       Impact factor: 3.452

Review 8.  Chemoradiation in pancreatic adenocarcinoma: a literature review.

Authors:  Rajarshi Roy; Anthony Maraveyas
Journal:  Oncologist       Date:  2010-03-04

9.  Long-term survival after multimodality treatment for resectable pancreatic cancer.

Authors:  H Ozaki; T Kinoshita; T Kosuge; K Shimada; J Yamamoto; K Tokuuye; N Fukushima; K Mukai
Journal:  Int J Pancreatol       Date:  2000-06

10.  Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma.

Authors:  R Krempien; M W Muenter; W Harms; J Debus
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.